Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
certain assets from other companies
|
| gptkbp:CEO |
Todd_C._Brady
|
| gptkbp:clinicalTrials |
ongoing
Phase 3 trials |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:develops |
ADX-2191
ADX-636 ADX-102 |
| gptkbp:focusesOn |
gene therapy
biologics visual impairment small molecules dry eye syndrome therapeutic antibodies retinal detachment diabetic retinopathy retinal diseases intraocular pressure age-related macular degeneration cell therapy allergic conjunctivitis treatment of autoimmune diseases ocular diseases corneal diseases ocular surface disease uveitis non-infectious anterior uveitis treatment of diseases related to the eye photophobia biomarkers in ocular diseases chronic dry eye clinical endpoints in eye diseases nanotechnology in ophthalmology ocular allergies ocular discomfort ocular drug delivery systems ocular inflammation ocular surface inflammation ocular surface repair patient-reported outcomes in ocular health surgical eye conditions tearing disorders uveitic macular edema ocular_pain |
| gptkbp:founded |
2011
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aldeyra Therapeutics
|
| gptkbp:investmentFocus |
institutional and retail investors
|
| gptkbp:marketSegment |
ALDX
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:publicTransport |
yes
|
| gptkbp:researchFocus |
inflammation
metabolic diseases |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple drug candidates
|
| gptkbp:website |
www.aldeyra.com
|